Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan once-weekly vs daily Norditropin in children with growth hormone deficiency
2018-000231-27Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity. Started Feb 2019; status: active.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2018-000231-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000231-27.